10 results on '"Ke, Mengying"'
Search Results
2. Clinical lipidomics analysis reveals biomarkers of lipid peroxidation in serum from patients with rheumatoid arthritis
- Author
-
Zhou, Guisheng, Lu, Jiawei, Xu, Tingting, Lu, Yan, Chen, Wenjun, Wang, Jue, Ke, Mengying, Shen, Qiuxiang, Zhu, Youjuan, Shan, Jinjun, and Liu, Shijia
- Published
- 2021
- Full Text
- View/download PDF
3. Serum metabolomic and lipidomic profiling identifies diagnostic biomarkers for seropositive and seronegative rheumatoid arthritis patients
- Author
-
Luan, Hemi, Gu, Wanjian, Li, Hua, Wang, Zi, Lu, Lu, Ke, Mengying, Lu, Jiawei, Chen, Wenjun, Lan, Zhangzhang, Xiao, Yanlin, Xu, Jinyue, Zhang, Yi, Cai, Zongwei, Liu, Shijia, and Zhang, Wenyong
- Published
- 2021
- Full Text
- View/download PDF
4. BUB1B and circBUB1B_544aa aggravate multiple myeloma malignancy through evoking chromosomal instability
- Author
-
Tang, Xiaozhu, guo, Mengjie, Ding, Pinggang, Deng, Zhendong, Ke, Mengying, Yuan, Yuxia, Zhou, Yanyan, Lin, Zigen, Li, Muxi, Gu, Chunyan, Gu, Xiaosong, and Yang, Ye
- Published
- 2021
- Full Text
- View/download PDF
5. GART Functions as a Novel Methyltransferase in the RUVBL1/β‐Catenin Signaling Pathway to Promote Tumor Stemness in Colorectal Cancer.
- Author
-
Tang, Chao, Ke, Mengying, Yu, Xichao, Sun, Shanliang, Luo, Xian, Liu, Xin, Zhou, Yanyan, Wang, Ze, Cui, Xing, Gu, Chunyan, and Yang, Ye
- Subjects
- *
COLORECTAL cancer , *CELLULAR signal transduction , *COLON tumors , *CATENINS , *CELL migration , *METHYLTRANSFERASES , *TUMOR growth , *WNT genes , *WNT signal transduction - Abstract
Tumor stemness is associated with the recurrence and incurability of colorectal cancer (CRC), which lacks effective therapeutic targets and drugs. Glycinamide ribonucleotide transformylase (GART) fulfills an important role in numerous types of malignancies. The present study aims to identify the underlying mechanism through which GART may promote CRC stemness, as to developing novel therapeutic methods. An elevated level of GART is associated with poor outcomes in CRC patients and promotes the proliferation and migration of CRC cells. CD133+ cells with increased GART expression possess higher tumorigenic and proliferative capabilities both in vitro and in vivo. GART is identified to have a novel methyltransferase function, whose enzymatic activity center is located at the E948 site. GART also enhances the stability of RuvB‐like AAA ATPase 1 (RUVBL1) through methylating its K7 site, which consequently aberrantly activates the Wnt/β‐catenin signaling pathway to induce tumor stemness. Pemetrexed (PEM), a compound targeting GART, combined with other chemotherapy drugs greatly suppresses tumor growth both in a PDX model and in CRC patients. The present study demonstrates a novel methyltransferase function of GART and the role of the GART/RUVBL1/β‐catenin signaling axis in promoting CRC stemness. PEM may be a promising therapeutic agent for the treatment of CRC. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Serum lipidomics reveals distinct metabolic profiles for asymptomatic hyperuricemic and gout patients.
- Author
-
Liu, Shijia, Wang, Yingzhuo, Liu, Huanhuan, Xu, Tingting, Wang, Ma-Jie, Lu, Jiawei, Guo, Yunke, Chen, Wenjun, Ke, Mengying, Zhou, Guisheng, Lu, Yan, Chen, Peidong, and Zhou, Wei
- Subjects
GOUT diagnosis ,HYPERURICEMIA ,BIOMARKERS ,TRIGLYCERIDES ,PREDICTIVE tests ,ACADEMIC medical centers ,HIGH performance liquid chromatography ,GLYCERIDES ,CONFIDENCE intervals ,METABOLOMICS ,DIFFERENTIAL diagnosis ,BLOOD collection ,DISCRIMINANT analysis ,COMPARATIVE studies ,RISK assessment ,DESCRIPTIVE statistics ,MASS spectrometry ,LOGISTIC regression analysis ,RECEIVER operating characteristic curves ,PHOSPHOLIPIDS ,SENSITIVITY & specificity (Statistics) ,LIPIDS ,GOUT ,METABOLITES ,LECITHIN ,DISEASE risk factors - Abstract
Objectives This study aimed to characterize the systemic lipid profile of patients with asymptomatic hyperuricemia (HUA) and gout using lipidomics, and to find potential underlying pathological mechanisms therefrom. Methods Sera were collected from Affiliated Hospital of Nanjing University of Chinese Medicine as centre 1 (discovery and internal validation sets) and Suzhou Hospital of Traditional Chinese Medicine as centre 2 (external validation set), including 88 normal subjects, 157 HUA and 183 gout patients. Lipidomics was performed by ultra high performance liquid chromatography plus Q-Exactive mass spectrometry (UHPLC-Q Exactive MS). Differential metabolites were identifed by both variable importance in the projection ≥1 in orthogonal partial least-squares discriminant analysis mode and false discovery rate adjusted P ≤ 0.05. Biomarkers were found by logistic regression and receiver operating characteristic (ROC) analysis. Results In the discovery set, a total of 245 and 150 metabolites, respectively, were found for normal subjects vs HUA and normal subjects vs gout. The disturbed metabolites included diacylglycerol, triacylglycerol (TAG), phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, etc. We also found 116 differential metabolites for HUA vs gout. Among them, the biomarker panel of TAG 18:1-20:0-22:1 and TAG 14:0-16:0-16:1 could differentiate well between HUA and gout. The area under the receiver operating characteristic ROC curve was 0.8288, the sensitivity was 82% and the specificity was 78%, at a 95% CI 0.747, 0.9106. In the internal validation set, the predictive accuracy of TAG 18:1-20:0-22:1 and TAG 14:0-16:0-16:1 panel for differentiation of HUA and gout reached 74.38%, while it was 84.03% in external validation set. Conclusion We identified serum biomarkers panel that have the potential to predict and diagnose HUA and gout patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Lipidomics Reveals Serum Specific Lipid Alterations in Diabetic Nephropathy.
- Author
-
Xu, Tingting, Xu, Xiaoyan, Zhang, Lu, Zhang, Ke, Wei, Qiong, Zhu, Lin, Yu, Ying, Xiao, Liangxiang, Lin, Lili, Qian, Wenjuan, Wang, Jue, Ke, Mengying, An, Xiaofei, and Liu, Shijia
- Subjects
DIABETIC nephropathies ,BLOOD lipids ,GLUCOSE metabolism disorders ,LIPID metabolism disorders ,RECEIVER operating characteristic curves ,DIABETES - Abstract
In diabetes mellitus (DM), disorders of glucose and lipid metabolism are significant causes of the onset and progression of diabetic nephropathy (DN). However, the exact roles of specific lipid molecules in the pathogenesis of DN remain unclear. This study recruited 577 participants, including healthy controls (HCs), type-2 DM (2-DM) patients, and DN patients, from the clinic. Serum samples were collected under fasting conditions. Liquid chromatography-mass spectrometry-based lipidomics methods were used to explore the lipid changes in the serum and identify potential lipid biomarkers for the diagnosis of DN. Lipidomics revealed that the combination of lysophosphatidylethanolamine (LPE) (16:0) and triacylglycerol (TAG) 54:2-FA18:1 was a biomarker panel for predicting DN. The receiver operating characteristic analysis showed that the panel had a sensitivity of 89.1% and 73.4% with a specificity of 88.1% and 76.7% for discriminating patients with DN from HCs and 2-DM patients. Then, we divided the DN patients in the validation cohort into microalbuminuria (diabetic nephropathy at an early stage, DNE) and macroalbuminuria (diabetic nephropathy at an advanced stage, DNA) groups and found that LPE(16:0), phosphatidylethanolamine (PE) (16:0/20:2), and TAG54:2-FA18:1 were tightly associated with the stages of DN. The sensitivity of the biomarker panel to distinguish between patients with DNE and 2-DM, DNA, and DNE patients was 65.6% and 85.9%, and the specificity was 76.7% and 75.0%, respectively. Our experiment showed that the combination of LPE(16:0), PE(16:0/20:2), and TAG54:2-FA18:1 exhibits excellent performance in the diagnosis of DN. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. Acupuncture Synergized With Bortezomib Improves Survival of Multiple Myeloma Mice via Decreasing Metabolic Ornithine.
- Author
-
Ke, Mengying, Qian, Jinjun, Hao, Feng, Li, Xinying, Wu, Hongjie, Luo, Xian, Xu, Bin, Gu, Chunyan, and Yang, Ye
- Subjects
MULTIPLE myeloma ,ORNITHINE ,OVERALL survival ,BORTEZOMIB ,ACUPUNCTURE - Abstract
Multiple myeloma (MM) is a hematological malignancy worldwide in urgent need for novel therapeutic strategies. Since Velcade (bortezomib) was approved for the treatment of relapsed/refractory MM in 2003, we have seen considerable improvement in extending MM patient survival. However, most patients are fraught with high recurrence rate and incurability. Acupuncture is known for alleviating patient symptoms and improving the quality of life, but it is not well investigated in MM, especially in combination with bortezomib. In this study, we employed LC-MS and UHPLC-MS together with bioinformatics methods to test serum samples from 5TMM3VT MM murine model mice with four different treatments [control (C) group, bortezomib (V) treatment group, acupuncture (A) group, and combined (VA) group]. MM mice in group VA had longer survival time than mice in group A or group V. Joint pathway analysis indicated the underlying arginine and proline metabolism pathway among the 32 significantly decreased metabolites in group VA. CCK-8 assay and in vivo experiments validated that ornithine, the metabolite of arginine, promoted MM cell proliferation. In addition, gene expression omnibus (GEO) database analysis suggested that MM patients with higher ornithine decarboxylase 1 (ODC1) expression were evidently associated with poor overall survival. In summary, this study demonstrates the synergistic effects of acupuncture and bortezomib on extending the survival of MM model mice and provides potential therapeutic targets in the treatment of MM. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. Untargeted lipidomics reveals specific lipid abnormalities in Sjögren's syndrome.
- Author
-
Lu, Jiawei, Guo, Yunke, Lu, Yan, Ji, Wei, Lin, Lili, Qian, Wenjuan, Chen, Wenjun, Wang, Jue, Lv, Xiangyu, Ke, Mengying, Kong, Deshun, Shen, Qiuxiang, Zhu, Youjuan, Liu, Ping, Su, Jinfeng, Wang, Lu, Li, Yuhua, Gao, Pan, Shan, Jinjun, and Liu, Shijia
- Subjects
BIOMARKERS ,TRIGLYCERIDES ,HIGH performance liquid chromatography ,DISCRIMINANT analysis ,SJOGREN'S syndrome ,RECEIVER operating characteristic curves ,LIPIDS ,METABOLITES ,LECITHIN - Abstract
Objective The relationship between serum lipid variations in SS and healthy controls was investigated to identify potential predictive lipid biomarkers. Methods Serum samples from 230 SS patients and 240 healthy controls were collected. The samples were analysed by ultrahigh-performance liquid chromatography coupled with Q Exactive™ spectrometry. Potential lipid biomarkers were screened through orthogonal projection to latent structures discriminant analysis and further evaluated by receiver operating characteristic analysis. Results A panel of three metabolites [phosphatidylcholine (18:0/22:5), triglyceride (16:0/18:0/18:1) and acylcarnitine (12:0)] was identified as a specific biomarker of SS. The receiver operating characteristic analysis showed that the panel had a sensitivity of 84.3% with a specificity of 74.8% in discriminating patients with SS from healthy controls. Conclusion Our approach successfully identified serum biomarkers associated with SS patients. The potential lipid biomarkers indicated that SS metabolic disturbance might be associated with oxidized lipids, fatty acid oxidation and energy metabolism. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Fibrinogen-Like Protein 1 Is a Novel Biomarker for Predicting Disease Activity and Prognosis of Rheumatoid Arthritis.
- Author
-
Liu, Shijia, Guo, Yunke, Lu, Lu, Lu, Jiawei, Ke, Mengying, Xu, Tingting, Lu, Yan, Chen, Wenjun, Wang, Jue, Kong, Deshun, Shen, Qiuxiang, Zhu, Youjuan, Tan, WenFeng, Ji, Wei, and Zhou, Wei
- Subjects
BIOMARKERS ,SJOGREN'S syndrome ,RECEIVER operating characteristic curves ,OSTEOARTHRITIS ,RHEUMATOID arthritis ,SYSTEMIC lupus erythematosus ,ANKYLOSING spondylitis - Abstract
Rheumatoid arthritis (RA), afflicting over 1% of the population, is an inflammatory joint disease leading to cartilage damage and ultimately impaired joint function. Disease-modifying anti-rheumatic drugs are considered as the first-line treatment to inhibit the progression of RA, and the treatment depends on the disease status assessment. The disease activity score 28 as clinical gold standard is extensively used for RA assessment, but it has the limitations of delayed assessment and the need for specialized expertise. It is necessary to discover biomarkers that can precisely monitor disease activity, and provide optimized treatment for RA patients. A total of 1,244 participants from two independent centers were divided into five cohorts. Cohorts 1–4 constituted sera samples of moderate to high active RA, low active RA, RA in remission and healthy subjects. Cohort 5 consisted of sera of RA, osteoarthritis (OA), ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), primary Sjogren's syndrome (pSS) and healthy subjects. Biomarkers were found from cohorts 1–2 (screening sets), cohort 3 (discovery and external validation sets), cohort 4 (drug intervention set) and cohort 5 (biomarker-specific evaluation set). We found 68 upregulated and 74 downregulated proteins by TMT-labeled proteomics in cohort 1, and fibrinogen-like protein 1 (FGL1) had the highest area under the receiver operating characteristic curve (AUC) values in cohort 2. In cohort 3, in cross-comparison among moderate/high active RA, low active RA, RA in remission and healthy subjects, FGL1 had AUC values of approximately 0.9000 and predictive values of 90%. Additionally, FGL1 had a predictive value of 91.46% for moderate/high active RA vs. remission/low active RA and 80.77% for RA in remission vs. low active RA in cohort 4. Importantly, FGL1 levels had no significant difference in OA and AS compared with healthy persons. The concentrations in SLE and pSS were improved, but approximately 3-fold lower than that in active RA in cohort 5. In summary, FGL1 is a novel and specific biomarker that could be clinically useful for predicting progression of RA. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.